EGFR and non-small cell lung carcinoma: Xu et al. evaluated the effect of consolidative LAT on oligometastatic stage IV EGFRm NSCLC without progression after first‐line EGFR TKI, and confirmed that patients with adrenal metastases gained an OS benefit from LAT (37.1 vs. 29.2 months, HR = 0.48, p = 0.032).